/PRVB

PRVB Stock - Provention Bio, Inc.

Q: What is the analyst price target for PRVB?

Analyst price target information is not currently available for PRVB.

Q: What is PRVB's market cap?

Market capitalization information is not currently available for PRVB.

Healthcare|Biotechnology|NASDAQ

$24.98+0.00%

+$0.00 (+0.00%) • Apr 26

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

100

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $27.48

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for PRVB

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2018

FY2019

FY2020

FY2021

FY2022

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta2.46

52W High$25.00

52W Low$3.19

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2022	FY2021	FY2020	FY2019	FY2018
Revenue	$12.89M	$1.40M	N/A	N/A	N/A
Gross Profit	$12.38M	$1.40M	N/A	N/A	N/A
Gross Margin	96.0%	100.0%	N/A	N/A	N/A
Operating Income	$-128,161,000	$-115,578,000	$-99,687,000	$-44,372,000	$-26,814,000
Net Income	$-113,565,000	$-114,432,000	$-98,581,000	$-42,198,000	$-26,478,000
Net Margin	-880.7%	-8203.0%	N/A	N/A	N/A
EPS	$-1.52	$-1.81	$-1.88	$-1.04	$-1.18

Company Overview

Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease; and a strategic collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. to develop and commercialize PRV-3279, a bispecific antibody-based molecule targeting the B cell surface proteins CD32B and CD79B in Greater China. Provention Bio, Inc. was incorporated in 2016 and is headquartered in Red Bank, New Jersey.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

100%

Hold / Neutral

Sell / Underperform

Analyst Consensus🟢 Bullish

1 Bullish0 Neutral/Bearish

Price Targets

$10

Average Target

↓ 60.0% Downside

Now

$10

Low

$10

Average

$10

High

Based on 1 analyst

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
September 20th 2022	Jefferies	Initiation	Buy	$10

Earnings History & Surprises

PRVB

Beat Rate

50%

Last 16 quarters

Avg Surprise

-7.4%

EPS vs Estimate

Beats / Misses

8/7

1 met exactly

Latest EPS

$-0.38

Q1 2023

EPS Surprise History

Q2 21

-8.3%

$-0.52vs$-0.48

Q3 21

+9.8%

$-0.46vs$-0.51

Q4 21

+8.5%

$-0.43vs$-0.47

Q1 22

+6.8%

$-0.41vs$-0.44

Q2 22

+22.2%

$-0.35vs$-0.45

Q3 22

+6.1%

$-0.46vs$-0.49

Q4 22

+26.1%

$-0.34vs$-0.46

Q1 23

-22.6%

$-0.38vs$-0.31

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q1 2024	Mar 27, 2024	—	—	—	—
Q4 2023	Nov 1, 2023	—	—	—	—
Q3 2023	Aug 2, 2023	$-1.54	—	—	—
Q2 2023	May 4, 2023	$-0.97	—	—	—
Q1 2023	Mar 29, 2023	$-0.31	$-0.38	-22.6%	✗ MISS
Q4 2022	Nov 3, 2022	$-0.46	$-0.34	+26.1%	✓ BEAT
Q3 2022	Aug 4, 2022	$-0.49	$-0.46	+6.1%	✓ BEAT
Q2 2022	May 5, 2022	$-0.45	$-0.35	+22.2%	✓ BEAT
Q1 2022	Feb 24, 2022	$-0.44	$-0.41	+6.8%	✓ BEAT
Q4 2021	Nov 4, 2021	$-0.47	$-0.43	+8.5%	✓ BEAT
Q3 2021	Aug 5, 2021	$-0.51	$-0.46	+9.8%	✓ BEAT
Q2 2021	May 6, 2021	$-0.48	$-0.52	-8.3%	✗ MISS
Q1 2021	Feb 25, 2021	$-0.50	$-0.58	-16.0%	✗ MISS
Q4 2020	Nov 5, 2020	$-0.40	$-0.56	-40.0%	✗ MISS
Q3 2020	Aug 6, 2020	$-0.25	$-0.45	-80.0%	✗ MISS
Q2 2020	May 7, 2020	$-0.26	$-0.26	0.0%	= MET
Q1 2020	Mar 12, 2020	$-0.23	$-0.22	+4.3%	✓ BEAT
Q4 2019	Nov 5, 2019	$-0.30	$-0.24	+20.0%	✓ BEAT
Q3 2019	Aug 6, 2019	$-0.31	$-0.32	-3.2%	✗ MISS
Q2 2019	May 8, 2019	$-0.19	$-0.29	-52.6%	✗ MISS